Ts-104
Phase 1
Ts-104 is one of 7 therapeutic programs targeting NSCLC (Non-small Cell Lung Cancer). It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
7 competitors in NSCLC (non-Small Cell Lung Cancer)
#DrugCompanyPhaseTrials
1Gavreto
RRigel Pharmaceuticals
Approved
Rasonque
Revolution MedicinesPhase 3
Beyfortus
BeiGenePhase 2
PD-1/PD-L1 Inhibitor
SSecond Affiliated Hospital of Soochow University
Phase 3
Surufatinib
HHutchison Medipharma Limited
Phase 2
Concurrent Chemotherapy
SSun Yat-sen University
Phase 2
Ts-104
TTwoStep Therapeutics, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Ts-104. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- TTwoStep Therapeutics, Inc.